These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16908983)

  • 1. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 6. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V; Herrling P
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract]   [Full Text] [Related]  

  • 7. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 8. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V; Herrling P
    Neurodegener Dis; 2011; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract]   [Full Text] [Related]  

  • 9. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 10. List of drugs in development for neurodegenerative diseases: update October 2011.
    Pogačić Kramp V
    Neurodegener Dis; 2012; 9(4):210-83. PubMed ID: 22222285
    [No Abstract]   [Full Text] [Related]  

  • 11. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulating the cell's appetite for itself.
    Simonsen A; Stenmark H
    Nat Chem Biol; 2007 Jun; 3(6):304-6. PubMed ID: 17510644
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 15. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heteroarylnitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties.
    Porcal W; Hernández P; González M; Ferreira A; Olea-Azar C; Cerecetto H; Castro A
    J Med Chem; 2008 Oct; 51(19):6150-9. PubMed ID: 18788732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotective effect of neurotrophic factors in experimental models of neurodegenerative disorders.
    Alberch J
    Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():63-4. PubMed ID: 9403862
    [No Abstract]   [Full Text] [Related]  

  • 20. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
    ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.